Efficacy of gerncitabine in heavily pretreated advanced ovarian cancer patients

Single agent gemcitabine was used in recurrent epithelial ovarian cancer patients after standard treatment with debulking surgery and platin-paclitaxel based chemotherapy. Response rates and toxicity results were evaluated retrospectively. Gemcitabine was given in 1000 mg/m2 intravenous infusion over 30 minutes at 1, 8, 15 days of every 28 days. Clinical response was evaluated with clinical findings, serum CA 125 levels, and computerized tomography. Twenty-two patients--ten as second-line, 11 as third-line, and one as fourth line--received gemcitabine. Seven patients received six courses, nine cases three, five cases two and one case one course of treatment. There were four (18.2%) partial and two (9.1%) complete responses with an overall response rate of 27.3%. Stable disease was also observed in three more cases. The progression-free interval was found to be a median of three months. Grade 3-4 neutropenia was seen in two (9.1%) and grade 3-4 thrombocytopenia was seen in four (18.2%) cases. Pancytopenia was observed in one (4.5%) patient. There was no grade 3-4 non-hematological toxicity. Antitumoral activity is encouraging in heavily pretreated ovarian cancer patients. A short progression-free interval is noticeable in responding cases. Toxicity is mainly hematologic and moderate.

Gemcitabine; Ovarian cancer; Chemotherapy; Toxicity

[1] Carmichael J.:'The role of gemcitabine in the treatment of other tumours". Br. J. Cancer, 1998, 78, S3, 21.

[2] Blackstein M., Vogel C. L., Ambinder R., Cowan J., Iglesias J., Melemed A.: "Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial". Oncology, 2002, 62, 2.

[3] Lund B., Hansen 0. P., Neijt J. P., T heilade K., Hansen M.: "Phase TT study of gemcitabine in previously platinum-treated ovarian cancer patients". Anticancer Drugs, 1995, 6 (Suppl.), 61.

[4] Shapiro J. D., Millward M. J., Rischin D., Michael M., Walcher V., Francis P.A., Toner G. C.: Gynecol. Oneal., 1996, 63, 89.

[5] Silver D. F., Piver M. S.: "Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum". Am. J. Clin. Oneal., 1999, 22, 450.

[6] Von Minckwitz G., Baukneckt T., Yisseren-Grul C. M., Neijt J. P.: "Phase II study of gemcitabine in ovarian cancer". Ann. Oneal., 1999, 10, 853.

[7] Friedlander M., Millward M. J., Be11 D., Bugat R., Harnett P., Moreno J. A. et al.: "A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer". Ann. Oneal., 1998, 9, 1343.